In November 2019, Aravive presented positive data from the ongoing Phase Ib portion of the Phase Ib/II trial of AVB-500 in platinum-resistant recurrent ovarian cancer, sending shares in the company soaring.

AVB-500 is an ultra-high affinity decoy protein that starves the GAS6/AXL signaling pathway of its signal by capturing circulating and bound GAS6, thereby potentially stopping the activation, migration and invasion of aberrant cells.

In studies to date, AVB-500 has demonstrated a favorable safety profile as a potential non-toxic drug that halts disease progression by effectively blocking GAS6/AXL signaling.